Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...
Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...
Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
CNBC’s Angelica Peebles and Novo Nordisk CEO Lars Fruergaard Jørgensen join 'Squawk Box' to discuss the company's quarterly ...